<DOC>
	<DOCNO>NCT00047229</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy doxorubicin use different way stop tumor cell divide stop grow die . Oblimersen may increase effectiveness doxorubicin make tumor cell sensitive drug . PURPOSE : Phase II trial study effectiveness combine oblimersen doxorubicin treat patient locally advance , recurrent , metastatic hepatocellular carcinoma ( liver cancer ) .</brief_summary>
	<brief_title>Oblimersen Doxorubicin Treating Patients With Advanced Hepatocellular Carcinoma ( Liver Cancer )</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose oblimersen doxorubicin patient advance hepatocellular carcinoma incurable solid tumor ( close accrual 11/7/03 ) . ( Phase I complete 1/16/04 . ) - Determine efficacy regimen , term objective response rate , patient . - Determine toxicity regimen patient . - Determine time progression , response duration , progression-free survival , median survival , overall survival rate patient treated regimen . OUTLINE : This dose-escalation , multicenter study . ( Phase I complete 1/16/04 . ) Patients receive oblimersen IV continuously day 1-7 doxorubicin IV 5 minute day 5 . Treatment repeat every 4 week 10 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos oblimersen doxorubicin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional patients* , include 6 patient hepatocellular carcinoma ( HCC ) , treat recommended phase II dose . ( Phase I complete 1/16/04 . ) NOTE : *Other solid tumor close accrual 11/7/03 ; accrue HCC patient PROJECTED ACCRUAL : A total 12-18 patient accrued phase I portion study within 6 month ( phase I complete 1/16/04 ) . A total 30 patient accrue phase II portion study within 10-15 month .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Histologically cytologically confirm hepatocellular carcinoma ( HCC ) Locally advance , recurrent , metastatic Not candidate surgical/radical therapy Other solid tumor incurable ( closed accrual 11/7/03 ) At least 1 unidimensionally measurable lesion At least 20 mm conventional technique OR least 10 mm spiral CT scan Target lesion may previously irradiate field unless subsequent progression document No ascites No known brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 OR Karnofsky 60100 % Life expectancy More 3 month Hematopoietic WBC least 2,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 2.0 mg/dL AST great 5 time upper limit normal ( ULN ) Albumin great 3.5 g/dL No cirrhosis worse ChildsPugh class A Renal Creatinine great 1.25 time ULN OR Creatinine clearance least 50 mL/min Cardiovascular LVEF normal MUGA No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other Good nutritional status No encephalopathy No concurrent uncontrolled illness No ongoing active infection No psychiatric illness social situation would preclude study participation No prior allergic reaction compound similar chemical biological composition oblimersen doxorubicin Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy No 1 prior biologic therapy regimen patient HCC At least 4 week since prior biologic therapy Chemotherapy Patients HCC : No prior systemic chemotherapy Prior chemotherapy part localize chemoembolization therapy may allow ( 150 mg/m^2 doxorubicin ) complete least 8 week study treatment All patient ( close accrual 11/7/03 ) : At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) No prior doxorubicin , epirubicin , anthracycline Endocrine therapy Not specify Radiotherapy See Disease Characteristics At least 4 week since prior radiotherapy No 3,000 cGy field include substantial bone marrow Surgery At least 8 week since prior surgery Prior liver transplant HCC allow Other Recovered prior therapy At least 8 week since locally ablative therapy No concurrent commercial investigational agent therapies No concurrent anticancer therapy No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
</DOC>